Evidence map›Paper›PMID 35508177›Full record

ArticleCell stem cell2022

Patient-derived micro-organospheres enable clinical precision oncology.

Shengli Ding, Carolyn Hsu, Zhaohui Wang, Naveen R Natesh, Rosemary Millen, Marcos Negrete, Nicholas Giroux, Grecia O Rivera, Anders Dohlman, Shree Bose and 27 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell stem cell, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 133 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
133citing papers in PubMed, 3 pooled it
17.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

133 citing papers in PubMed, 3 syntheses or guidelines pooled it, 189 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Article
  6. Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Article
  14. New developments and applications of human organoids.Nature reviews. Molecular cell biology · 2026
    Review
  15. Organoid technology in cancer research.Molecular biomedicine · 2026
    Review
  16. Review
  17. Article
  18. Review
  19. Article
  20. Review

73 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

37 authors at 8 institutions in 4 countries.

Shengli DingDepartment of Biomedical Engineering, Pratt School of Engineering, Duke University, Durham, NC 27708, USA; Xilis, Inc., Durham, NC 27713, USA.
Carolyn HsuCollege of Arts and Sciences, University of Chapel Hill, Chapel Hill, NC 27599, USA.
Zhaohui WangDepartment of Biomedical Engineering, Pratt School of Engineering, Duke University, Durham, NC 27708, USA; Xilis, Inc., Durham, NC 27713, USA.
Naveen R NateshDepartment of Biomedical Engineering, Pratt School of Engineering, Duke University, Durham, NC 27708, USA.
Rosemary MillenOncode, Hubrecht Institute, Royal Netherlands Academy of Arts and Sciences (KNAW), University Medical Center (UMC) Utrecht, Uppsalalaan 8, 3584 CT Utrecht, the Netherlands.
Marcos NegreteDepartment of Biomedical Engineering, Pratt School of Engineering, Duke University, Durham, NC 27708, USA.
Nicholas GirouxDepartment of Biomedical Engineering, Pratt School of Engineering, Duke University, Durham, NC 27708, USA.
Grecia O RiveraDepartment of Biomedical Engineering, Pratt School of Engineering, Duke University, Durham, NC 27708, USA.
Anders DohlmanDepartment of Biomedical Engineering, Pratt School of Engineering, Duke University, Durham, NC 27708, USA.
Shree BoseDepartment of Biomedical Engineering, Pratt School of Engineering, Duke University, Durham, NC 27708, USA.
Tomer RotsteinDepartment of Biomedical Engineering, Pratt School of Engineering, Duke University, Durham, NC 27708, USA.
Kassandra SpillerXilis, Inc., Durham, NC 27713, USA.
Athena YeungDepartment of Biomedical Engineering, Pratt School of Engineering, Duke University, Durham, NC 27708, USA.
Zhiguo SunDepartment of Biomedical Engineering, Pratt School of Engineering, Duke University, Durham, NC 27708, USA.
Chongming JiangDepartment of Medicine, Baylor College of Medicine, Houston, TX 77030, USA.
Rui XiDepartment of Biomedical Engineering, Pratt School of Engineering, Duke University, Durham, NC 27708, USA.
Benjamin WilkinXilis, Inc., Durham, NC 27713, USA.
Peggy M RandonNational Institute of Environmental Health Sciences (NIEHS), Durham, NC 27709, USA.
Ian WilliamsonDepartment of Biomedical Engineering, Pratt School of Engineering, Duke University, Durham, NC 27708, USA.
Daniel A NelsonXilis, Inc., Durham, NC 27713, USA.
Daniel DelubacXilis, Inc., Durham, NC 27713, USA.
Sehwa OhDivision of Medical Oncology, Duke Cancer Institute, Duke University, Durham, NC 27708, USA.
Gabrielle RupprechtDivision of Medical Oncology, Duke Cancer Institute, Duke University, Durham, NC 27708, USA.
James IsaacsDivision of Medical Oncology, Duke Cancer Institute, Duke University, Durham, NC 27708, USA.
Jingquan JiaDivision of Medical Oncology, Duke Cancer Institute, Duke University, Durham, NC 27708, USA.
Chao ChenDepartment of Medicine, Baylor College of Medicine, Houston, TX 77030, USA.
John Paul ShenDepartment of Gastrointestinal Medical Oncology, MD Anderson, Houston, TX 77030, USA.
Scott KopetzDepartment of Gastrointestinal Medical Oncology, MD Anderson, Houston, TX 77030, USA.
Shannon McCallDepartment of Pathology, Duke University, Durham, NC 27708, USA.
Amber SmithXilis, Inc., Durham, NC 27713, USA.
Nikolche GjorevskiRoche Pharmaceutical Research and Early Development, Roche Innovation Center, Basel 4058, Switzerland.
Antje-Christine WalzRoche Pharmaceutical Research and Early Development, Roche Innovation Center, Basel 4058, Switzerland.
Scott AntoniaDivision of Medical Oncology, Duke Cancer Institute, Duke University, Durham, NC 27708, USA.
Estelle Marrer-BergerRoche Pharmaceutical Research and Early Development, Roche Innovation Center, Basel 4058, Switzerland.
Hans CleversPrincess Máxima Center for Pediatric Oncology, Heidelberglaan 25, 3584 CS Utrecht, the Netherlands; Oncode, Hubrecht Institute, Royal Netherlands Academy of Arts and Sciences (KNAW), University Medical Center (UMC) Utrecht, Uppsalalaan 8, 3584 CT Utrecht, the Netherlands; Roche Pharmaceutical Research and Early Development, Roche Innovation Center, Basel 4058, Switzerland. Electronic address: h.clevers@hubrecht.eu.
David HsuDivision of Medical Oncology, Duke Cancer Institute, Duke University, Durham, NC 27708, USA. Electronic address: shiaowen.hsu@duke.edu.
Xiling ShenDepartment of Biomedical Engineering, Pratt School of Engineering, Duke University, Durham, NC 27708, USA; Terasaki Institute for Biomedical Innovation, Los Angeles, CA 90024, USA. Electronic address: xiling.shen@terasaki.org.
Duke University · USDuke Medical Center · USRoche (Switzerland) · CHBaylor College of Medicine · USThe University of Texas MD Anderson Cancer Center · USNational Institute of Environmental Health Sciences · USRoyal Netherlands Academy of Arts and Sciences · NLUniversity of North Carolina at Chapel Hill · US

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8M
Women's Cancer Research ProgramP30CA014236 · NCI · DUKE UNIVERSITY · PI DONNA NIEDZWIECKI · 1985 to 2026
$174.8M
MEDICAL SCIENTIST TRAINING PROGRAMT32GM007171 · NIGMS · DUKE UNIVERSITY · PI KONTOS, CHRISTOPHER D · 1985 to 2021
$31.2M
Medical Scientist Training Program Training GrantT32GM145449 · NIGMS · DUKE UNIVERSITY · PI Christopher D Kontos · 2022 to 2026
$6.6M
Robust Control of the Stem Cell NicheR35GM122465 · NIGMS · TERASAKI INSTITUTE FOR BIOMEDICAL INNOVATION · PI Xiling Shen · 2017 to 2026
$5.6M
An organotypic model recapitulating colon cancer microenvironment and metastasisU01CA214300 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI HUANG, EMINA HUI-NA, SHEN, XILING · 2017 to 2021
$3.1M
Epigenomic Reprogramming in Patient Derived Models of Colorectal CancerU01CA217514 · NCI · DUKE UNIVERSITY · PI HSU, SHIAOWEN DAVID · 2018 to 2022
$3.1M
Duke-UNC Chapel Hill Immunotherapy Training GrantT32CA211056 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI CHAO, NELSON J., SERODY, JONATHAN S. · 2017 to 2021
$2.2M
NCI NIH HHS P30 CA014236NCI NIH HHS P30 CA016672NCI NIH HHS T32 CA211056NCI NIH HHS U01 CA214300NCI NIH HHS U01 CA217514NIGMS NIH HHS R35 GM122465NIGMS NIH HHS T32 GM007171NIGMS NIH HHS T32 GM145449
6 · The paper itself

Abstract

Patient-derived xenografts (PDXs) and patient-derived organoids (PDOs) have been shown to model clinical response to cancer therapy. However, it remains challenging to use these models to guide timely clinical decisions for cancer patients. Here, we used droplet emulsion microfluidics with temperature control and dead-volume minimization to rapidly generate thousands of micro-organospheres (MOSs) from low-volume patient tissues, which serve as an ideal patient-derived model for clinical precision oncology. A clinical study of recently diagnosed metastatic colorectal cancer (CRC) patients using an MOS-based precision oncology pipeline reliably assessed tumor drug response within 14 days, a timeline suitable for guiding treatment decisions in the clinic. Furthermore, MOSs capture original stromal cells and allow T cell penetration, providing a clinical assay for testing immuno-oncology (IO) therapies such as PD-1 blockade, bispecific antibodies, and T cell therapies on patient tumors.

Indexed as

Colonic NeoplasmsPrecision MedicineHumansImmunotherapyOrganoidsadoptive cell therapybispecific antibodycolorectal cancerdroplet microfluidicsimmune-oncologylung cancermicro-organosphereprecision medicineprecision oncologytumorsphere

Identifiers

PMID35508177
PMCPMC9177814
OpenAlexW4225318180

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.